VXFVanguard Extended Market ETF

The payment gives Aligos non-dilutive funding as it advances its pipeline of treatments for liver and viral diseases.

Unicycive Therapeutics said on Tuesday that the U.S. Food and Drug Administration has again refused to approve its drug oxylanthanum carbonate.

The drop follows four straight days of the stock closing in the green.

The U.S. Food and Drug Administration (FDA) cleared Gain Therapeutics to begin a mid-stage clinical trial of its experimental drug GT-02287 in people with Parkinson’s disease.

Unicyive is awaiting word on whether its main drug, oxylanthanum carbonate, will be approved to treat hyperphosphatemia in patients with chronic kidney disease on dialysis.

Legal challenges also loom for the firm, as the Rosen Law Firm probes possible securities class action claims which critics say could push Strategy into bankruptcy.

Unicyive Therapeutics is awaiting word on whether its main drug, oxylanthanum carbonate, will be approved to treat hyperphosphatemia in patients with chronic kidney disease on dialysis following a previous rejection.

Passage Bio said on Wednesday that it will merge with privately held Remix Therapeutics.

Every four pre-split shares were consolidated into one new share, with trading beginning on a split-adjusted basis on Tuesday.